US2023192687A1PendingUtilityA1

Fused amino pyridine as hsp90 inhibitors

Assignee: CURIS INCPriority: Mar 20, 2007Filed: Dec 15, 2022Published: Jun 22, 2023
Est. expiryMar 20, 2027(~0.7 yrs left)· nominal 20-yr term from priority
A61K 31/437A61K 31/4545Y02A50/30C07D 471/04A61P 35/00A61P 35/04A61P 25/28A61P 35/02A61P 9/00A61P 21/00A61K 31/44A61P 25/00C07D 401/12A61P 43/00A61P 27/02A61P 37/02A61P 25/14A61P 25/16A61P 37/06A61P 31/04C07D 487/04
86
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

Claims

exact text as granted — not AI-modified
1 . A method of treating inflammatory diseases or immune system disorders in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound represented by formula I: 
       
         
           
           
               
               
           
         
       
       or a geometric isomer, enantiomer, diastereomer, racemate, pharmaceutically acceptable salt, prodrug or solvate thereof, wherein;
 U is N or CH;
 W is hydrogen, halogen, amino, hydroxy, thiol, alkyl, substituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylthio, substituted or unsubstituted alkylsulfonyl, CF 3 , NO 2 , CN, N 3 , sulfonyl, acyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, or substituted cycloalkyl; 
 X is absent, O, S, S(O), S(O) 2 , N(R 8 ), C(O), CF 2 , C(R 8 ) or C 2 -C 6  alkyl, C 2 -C 6  alkenyl, C 2 -C 6  alkynyl in which one or more methylene can be interrupted or terminated by O, S, SO, SO 2 , N(R 8 ), C(O), where R 8  is hydrogen, acyl, aliphatic or substituted aliphatic; 
 Y is independently hydrogen, halogen, NO 2 , CN, or lower alkyl; 
 Z is amino, substituted or unsubstituted alkylamino, substituted or unsubstituted dialkylamino, substituted or unsubstituted alkylcarbonylamino; 
 Q is aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, or heterocycloalkyl; 
 
 
       V is hydrogen, straight- or branched-, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, which one or more methylenes can be interrupted or terminated by O, S, S(O), SO 2 , N(R 8 ), C(O), substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic; substituted or unsubstituted cycloalkyl; where R 8  is hydrogen, acyl, aliphatic or substituted aliphatic. 
     
     
         2 - 24 . (canceled)

Join the waitlist — get patent alerts

Track US2023192687A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.